Literature DB >> 11701697

Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study.

T Pal1, F D Vogl, P O Chappuis, R Tsang, J Brierley, H Renard, K Sanders, T Kantemiroff, S Bagha, D E Goldgar, S A Narod, W D Foulkes.   

Abstract

The genetic basis for nonmedullary forms of thyroid cancer (NMTC) is less well established than that of medullary thyroid cancer. However, epidemiological and family studies suggest that a proportion of NMTC may be due to inherited predisposition. To estimate the familial risk of thyroid cancer, we conducted a hospital-based case-control study at the Princess Margaret Hospital in Toronto, Ontario, Canada, and at 2 university hospitals in Montréal, Québec, Canada. We obtained pedigrees from 339 unselected patients diagnosed with NMTC and from 319 unaffected ethnically matched controls. Family histories of cancer were obtained from the cases and controls for 3292 first degree relatives of cases and controls. Seventeen cases (5.0%) and 2 controls (0.6%) reported at least one first degree relative with thyroid cancer. In relatives of patients with thyroid cancer, the incidence of any type of cancer (including NMTC) was 38% higher than in relatives of controls (incidence rate ratio, 1.4; 95% confidence interval, 1.1-1.7). The relative risk for thyroid cancer was 10-fold higher in relatives of cancer patients than in controls (incidence rate ratio, 10.3; 95% confidence interval, 2.2-47.6). Our findings suggest that hereditary or other familial factors are important in a small proportion of NMTC. Molecular studies are needed to determine the genetic basis of cancer susceptibility in these families.

Entities:  

Mesh:

Year:  2001        PMID: 11701697     DOI: 10.1210/jcem.86.11.8010

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  41 in total

1.  Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.

Authors:  J D McKay; D Thompson; F Lesueur; K Stankov; A Pastore; C Watfah; S Strolz; G Riccabona; R Moncayo; G Romeo; D E Goldgar
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

2.  The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.

Authors:  Young Joo Park; Hwa Young Ahn; Hoon Sung Choi; Kyung Won Kim; Do Joon Park; Bo Youn Cho
Journal:  Thyroid       Date:  2012-01-26       Impact factor: 6.568

3.  2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.

Authors:  Andrei Iagaru; Rinat Masamed; Peter A Singer; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

4.  Does familial non-medullary thyroid cancer adversely affect survival?

Authors:  Frederic Triponez; Mariwil Wong; Cord Sturgeon; Nadine Caron; David G Ginzinger; Mark R Segal; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 5.  Controversies in familial thyroid cancer 2014.

Authors:  Orlo H Clark
Journal:  Ulus Cerrahi Derg       Date:  2014-06-01

6.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.

Authors:  Chunkit Fung; Sophie D Fossa; Michael T Milano; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 7.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 8.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

9.  Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma.

Authors:  Hugo João Prazeres; Fernando Rodrigues; Paula Soares; Plamen Naidenov; Paulo Figueiredo; Beatriz Campos; Manuela Lacerda; Teresa C Martins
Journal:  Fam Cancer       Date:  2007-09-07       Impact factor: 2.375

10.  The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.

Authors:  Iñigo Landa; Sergio Ruiz-Llorente; Cristina Montero-Conde; Lucía Inglada-Pérez; Francesca Schiavi; Susanna Leskelä; Guillermo Pita; Roger Milne; Javier Maravall; Ignacio Ramos; Víctor Andía; Paloma Rodríguez-Poyo; Antonino Jara-Albarrán; Amparo Meoro; Cristina del Peso; Luis Arribas; Pedro Iglesias; Javier Caballero; Joaquín Serrano; Antonio Picó; Francisco Pomares; Gabriel Giménez; Pedro López-Mondéjar; Roberto Castello; Isabella Merante-Boschin; Maria-Rosa Pelizzo; Didac Mauricio; Giuseppe Opocher; Cristina Rodríguez-Antona; Anna González-Neira; Xavier Matías-Guiu; Pilar Santisteban; Mercedes Robledo
Journal:  PLoS Genet       Date:  2009-09-04       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.